Breaking News, Collaborations & Alliances

Genprex Partner Aldevron Completes Step in Mfg. for Oncoprex Clinical Devt. Program

Newly manufactured plasmids will be used in clinical trials evaluating Oncoprex in combination with targeted therapies and immunotherapies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Clinical-stage gene therapy company Genprex, said that that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA pursuant to the manufacturing agreement between Genprex and Aldevron that was announced in September 2018.   Genprex’s initial product candidate, Oncoprex consists of a TUSC2 plasmid DNA manufactured by Aldevron encapsulated in a nanovesicle made from lipid molecules with a positive electrical charge....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters